Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Treatment with Finerenone on Cardio-Renal Target Organ Damage in Patients with Type 2 Diabetes
2023-504446-58-00Phase 4Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Finerenone (Kerendia) with Placebo (2 arms). Primary endpoints: Change in left ventricular mass and Change in albuminuria (UACR). Planned start Sep 2024; status: authorised.
02
Drugs
finerenone
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-504446-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504446-58-00.